We are live on ! Find out more
ANIX icon

Anixa Biosciences
ANIX

16 hedge funds and large institutions have $4.32M invested in Anixa Biosciences in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

23% more funds holding

Funds holding: 13 → 16 (+3)

1.11% more ownership

Funds ownership: 4.75% → 5.86% (+1.1%)

5% more capital invested

Capital invested by funds: $4.12M → $4.32M (+$198K)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$427K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$263K
3
UBS Group
UBS Group
Switzerland
+$127K
4
Northern Trust
Northern Trust
Illinois
+$73.7K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$4.59K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$7.27K
2
Bank of America
Bank of America
North Carolina
-$1.85K
3
Wells Fargo
Wells Fargo
California
-$1.07K

ANIX Hedge Fund Activity: Q4 2018 in Review

16 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2018, worth a combined $4.32M — up 4.8% from $4.12M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ANIX positions and 0 closed out — a net gain of 3 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $427K. The largest seller was JP Morgan Chase, cutting an estimated $7.27K.

  • 16 institutional investors held Anixa Biosciences (ANIX) as of Q4 2018, up from 13 in Q3 2018.
  • Funds reported $4.32M of Anixa Biosciences stock for Q4 2018, up 4.8% quarter-over-quarter.
  • 3 funds opened new Anixa Biosciences positions in Q4 2018 and 0 closed out, a net change of +3 holders.
  • The largest Anixa Biosciences buyer in Q4 2018 was Geode Capital Management, an estimated $427K added.
  • The largest Anixa Biosciences seller in Q4 2018 was JP Morgan Chase, an estimated $7.27K sold.

Based on aggregated 13F filings for Q4 2018.